Treatment using herpes simplex virus

Details Treatment using herpes simplex virus Treatment using herpes simplex virus

2011-03-01

2011-03-01

Paras, Jr., Peter (Department: 1632)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

C424S205100, C424S231100, C435S320100, C435S455000, C514S04400A

Reexamination Certificate

active

07897146

ABSTRACT:
The use of Herpes Simplex Virus (HSV) in the treatment of tumour by extratumoural administration of HSV, and the use of HSV in treatment of tumour by combination therapy with a pharmaceutical wherein the HSV and/or pharmaceutical is administered at an extratumoural location, is disclosed.

REFERENCES:
patent: 5922576 (1999-07-01), He et al.
patent: 6114146 (2000-09-01), Herlitschka et al.
patent: 6573090 (2003-06-01), Breakefield et al.
patent: 0353851 (1990-02-01), None
patent: 0538496 (1993-04-01), None
patent: 0753581 (1997-01-01), None
patent: 93/08288 (1993-04-01), None
patent: 95/04139 (1995-02-01), None
patent: 96/03997 (1996-02-01), None
patent: 96/05291 (1996-02-01), None
patent: 97/04804 (1997-02-01), None
patent: 97/14808 (1997-04-01), None
patent: 97/26904 (1997-07-01), None
patent: 98/51809 (1998-11-01), None
patent: 99/38955 (1999-08-01), None
patent: 99/55345 (1999-11-01), None
patent: 01/16331 (2001-03-01), None
patent: 01/46449 (2001-06-01), None
patent: 01/53506 (2001-07-01), None
patent: 03/018788 (2003-03-01), None
patent: 03/068809 (2003-08-01), None
patent: 2005/049844 (2005-06-01), None
patent: 2005/049845 (2005-06-01), None
patent: 2005/049846 (2005-06-01), None
patent: 2007/132169 (2007-11-01), None
patent: 2008/099189 (2008-08-01), None
patent: 2009/013448 (2009-01-01), None
Moriuchi et al., (2002, vol. 9, pp. 584-591.
Concalves et al., 2005, BioEssays, vol. 27, pp. 506-517.
Haura et al., 2003, Molecular Biotechnology, vol. 25, pp. 139-148.
Verma et al., 2005, Annu. Rev. Biochem. vol. 74, pp. 711-738.
Parekh-Olmedo et al., 2005, Gene Therapy, vol. 12, pp. 639-646.
Bilsland, Alan E., “Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase,” Oncogene, 2003, vol. 22, pp. 370-380.
Bryant, Christopher, et al., “Cloning, Nucleotide Sequence, and Expression of the Nitroreductase Gene fromEnterobacter cloacae,” The Journal of Biological Chemistry, 1991, vol. 296, pp. 4126-4130.
Coukos, George, et al., “Use of Carrier Cells to Deliver a Replication-selective Herpes Simplex Virus-1 Mutant for the intraperitoneal Therapy of Epithelial Ovarian Cancer,” Clinical Cancer Research, 1999, vol. 5, pp. 1523-1537.
Dachs, Gabi U., et al., “From bench to bedside for gene-directed enzyme prodrug therapy of cancer,” Anti-Cancer Drugs, 2005, vol. 16, pp. 349-359.
Fu, Xinping, et al., “Expression of a Fusogenic Membrane Glycoprotein by an Oncolytic Herpes Simplex Virus Potentiates the Viral Antitumor Effect,” molecular Therapy, 2003, vol. 7, pp. 748-754.
Gomez-Lira, Macarena, et al., “CD45 and multiple sclerosis: the exon 4 C77G polymorphism (additional studies and meta-analysis) and new markers,” Journal of Neuroimmunology, 2003, vol. 140, pp. 216-221.
Goncalves, Manuel A.F.V., “A concise peer into the background, initial thoughts and practices of human gene therapy,” BioEssays, 2005, vol. 27, pp. 506-517.
Haura, Eric B., “Gene Therapy for Lung Cancer,” Molecular Biotechnology, 2003, vol. 25, pp. 139-148.
Jorgensen, Timothy J., “Ionizing Radiation Does Not Alter the Antitumor Activity of Herpes Simplex Virus Vector G207 in Subcutaneous Tumor Models of Human and Murine Prostate Cancer,” Neoplasia, vol. 3, pp. 451-456.
Liu, B.L., et al., “ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties,” Gene Therapy, 2003, vol. 10, pp. 292-303.
Markert, J.M., “Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial,” Gene Therapy, 2000, vol. 7, pp. 867-874.
McNeish, I.A., et al., “Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally deliveredE. colinitroreductase and CB1954,” Gene Therapy, 1998, vol. 5, pp. 1061-1069.
Moriuchi, S., et al., “Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model,” Gene Therapy, 2002, vol. 9, pp. 584-591.
Nakamori, Mikihito, et al., “Effective Therapy of Metastatic Ovarian Cancer with an Oncolytic Herpes Simplex Virus Incorporating Two Membrane Fusion Mechanisms,” Clinical Cancer Research, 2003, vol. 9, pp. 2727-2733.
Nakamori, Mikihito, et al., “Potent Antitumor Activity After Systemic Delivery of a Doubly Fusogenic Oncolytic Herpes Simplex Virus Against Metastatic Prostate Cancer,” The Prostate, 2004, vol. 60, pp. 53-60.
Palmer, Daniel H., et al. “Virus-Directed Enzyme Prodrg Therapy: Intratumoral Administration of a Replication-Deficient Adenovirus Encoding Netroreductase to Patients with Resectable Liver Cancer,” Journal of Clinical Oncology, 2004, vol. 22, pp. 1546-1552.
Parekh-Olmedo, H., et al., “Gene therapy progress and prospects: targeted gene repair,” Gene Therapy, 2005, vol. 12, pp. 639-646.
Perna, Nicole T., et al., “Genome sequence of enterohaemorrhagicEscherichia coli0157:H7,” Nature, 2001, vol. 409, pp. 529-533.
Toyoizumi, Takane, et al., “Combined Therapy with Chemotherapeutic Agents and Herpes Simplex Virus Type 1 ICP34.5 Mutant (HSV-1716) in Human Non-Small Cell Lung Cancer,” Human Gene Therapy, 1999, vol. 10, pp. 3013-3029.
Varghese, Susan; Rabkin, Samuel D., “Oncolytic herpes simplex virus vectors for cancer virotherapy,” Cancer Gene Therapy, 2002, vol. 9, pp. 967-978.
Verma, Inder M., et al., “Gene Therapy: Twenty-First Century Medicine,” Annual Review of Biochemistry, 2005, vol. 74, pp. 711-738.
Walker, Jonathan R., et al. “Local and Systemic Therapy of Human Prostate Adenocarcinoma with the Conditionally Replicating Herpes Simplex Virus Vector G207,” Human Gene Therapy, 1999, vol. 10, pp. 2237-2243.
Watanabe, Masahiko, et al., “Nucleotide sequence ofSalmonella typhimuriumnitroreductase gene,” Nucleic Acids Research, Submitted Jan. 5, 1990, vol. 18, No. 4, p. 1059.
Weedon, Sarah J., et al., “Sensitisation of Human Carcinoma Cells to the Prodrug CB1954 by Adenovirus Vector-Mediated Expression ofE. coliNitroreductase,” International Journal of Cancer, 2000, vol. 86, pp. 848-854.
Wong, Richard J., et al., “Oncolytic Herpesvirus Effectively Treats Murine Squamous Cell Carcinoma and Spreads by Natural Lymphatics to Treat Sites of Lymphatic Metastases,” Human Gene Therapy, 2002, vol. 13, pp. 1213-1223.
Chou et al. (1990) Science, 250:1262-1266, “Mapping of herpes simplex virus-1 neurovirulence toγ134.5, a gene nonessential for growth in culture”.
Kucharczuk et al (1997) Cancer Research, 57:466-471, “Use of a “Replication-Restricted” Herpes Virus to Treat Experimental Human Malignant Mesothelioma”.
Lovering et al. (2001) J. Mol. Biol. 309:203-213, “The structure ofEscherichia colinitroreductase complexed with nicotinic acid: three crystal forms at 1.7 A, 1.8 A and 2.4 A resolution”.
Liu et al (2003) Gene Therapy 10:292-303 “ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties”.
Mackie et al (2001) The Lancet 357:525 “Intralesional injection of herpes simplex virus 1716 in metastatic melanoma”.
MacLean et al. (1991) Journal of General Virology, 72:631-639, “Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+between immediate early gene 1 and the ‘a’ sequence”.
Parkinson et al. (2000) J. Med. Chem. 43:3624-3631, “Crystal structure of FMN-dependent nitroreductase fromEscherichia coliB: a prodrug-activating enzyme”.
Randazzo et al (1997) J. Invest Dermatol 108:933-937, “Treatment of Experimental Subcutaneous Human Melanoma with a Replication-Restricted Herpes Simplex Virus Mutant”.
Toda et al (1998)

Affiliated with

Also associated with

Rating

Treatment using herpes simplex virus does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment using herpes simplex virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment using herpes simplex virus will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2716853